ArticleHepatology (Baltimore, Md.)2012
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients.PloS one · 2013Trial
- Association of testosterone and sex hormone-binding globulin with chronic liver disease outcomes across sex and menopausal status.Biology of sex differences · 2026Article
- China data on the burden of alcohol-associated liver cancer from 1990 to 2021: a systematic analysis from the global burden of disease study 2021.Ecancermedicalscience · 2026Article
- Trends in liver cancer rehabilitation needs, disease burden, and attributable risk factors in China, 1990-2021.Scientific reports · 2025Article
- Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.The world journal of men's health · 2025Article
- Estrogen and viral infection.Frontiers in immunology · 2025Review
- Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends.Cancer biology & medicine · 2024Article
- The Influence of Urbanization on the Patterns of Hepatocellular Carcinoma Mortality From 1999 to 2020.Gastroenterology research · 2024Article
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.Nature reviews. Clinical oncology · 2023Review
- Sex differences in chronic liver disease and benign liver lesions.JHEP reports : innovation in hepatology · 2023Review
- Protective Effect of Daidzein against Diethylnitrosamine/Carbon Tetrachloride-Induced Hepatocellular Carcinoma in Male Rats.Biology · 2023Article
- [Global liver cancer incidence and mortality and future trends from 2000 to 2020: GLOBOCAN data analysis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Burden of liver cancer due to hepatitis C from 1990 to 2019 at the global, regional, and national levels.Frontiers in oncology · 2023Article
- The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study.European journal of medical research · 2022Article
- The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones.Frontiers in immunology · 2022Review
- Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series.Vaccines · 2021Review
- Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.Drug discovery today · 2021Review
- Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States.Scientific reports · 2020Article
- Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy.Infectious agents and cancer · 2020Article
- Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
unlabelledMales have strikingly increased risk of advanced liver disease. However, the association between testosterone and risk of hepatitis C virus (HCV)-related advanced liver disease is unknown. We performed a cross-sectional study in male veterans with chronic HCV. Blood samples were obtained to measure total serum testosterone and perform the FibroSURE-ActiTest. Other risk-factor data were obtained through systematic questionnaires (e.g., alcohol), physical measurements (e.g., body mass index), and serological tests (e.g., viral load). The association between total testosterone and risk of advanced hepatic fibrosis (F3 and F3/F4) and inflammatory activity (A3 and A2/3) measured by the FibroSURE-ActiTest was evaluated with logistic regression. A total of 308 eligible study participants were prospectively recruited (mean age: 57; 52% African-American). There were 105 cases with advanced fibrosis and 203 mild fibrosis controls as well as 88 cases with advanced inflammatory activity and 220 mild activity controls. Mean total serum testosterone was significantly higher in advanced fibrosis cases as well as advanced inflammatory activity cases, compared to mild disease controls (6.0 versus 5.3 ng/mL and 5.9 versus 5.4 ng/mL, respectively). We observed a significant 25% increase in advanced fibrosis risk and 15% increase in advanced inflammatory activity risk for each 1-ng/mL increase in total serum testosterone. Total testosterone in the upper tertile was associated with an even greater excess risk of advanced fibrosis than advanced inflammatory activity (odds ratio [OR](adjusted advanced fibrosis) = 3.74; 95% CI: 1.86-6.54 versus OR(adjusted advanced inflammatory activity) = 2.23; 95% CI: 1.07-4.93, respectively).
conclusionsTotal serum testosterone is associated with an increased risk of both advanced hepatic fibrosis and advanced hepatic inflammatory activity in HCV-infected men. Testosterone may be important in the pathogenesis of HCV-related advanced liver disease in males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.